News | August 23, 2011

Study Reflects Achievements of ACC’s Door-to-Balloon Campaign

August 23, 2011 — A new study shows heart attack patients are now being treated an average of 32 minutes faster than five years ago. This provides evidence of a national campaign's success to treat heart attacks within 90 minutes in order to reduce heart damage and costs associated with treatment. This is according to David Holmes, M.D., FACC, president of the American College of Cardiology (ACC).

The study “Improvements in Door-to-Balloon Time (D2B) in the United States: 2005-2010” found the average time from hospital arrival to treatment declined from 96 minutes in 2005 to 64 minutes in 2010. In addition, more than 90 percent of heart attack patients requiring emergency angioplasty in 2010 received treatment within the recommended 90 minutes, up from 44 percent in 2005.

“We are not done. We intend to remain focused on providing training and feedback in the form of data from our registries to maintain these gains while continuing to look for ways to improve,” Holmes said. “Another piece of the time-to-treatment equation is time lost when patients are transferred in to a referral center. Coordinated systems of care in which patients are taken directly to a hospital equipped to perform angioplasty and insert stents or are transferred quickly are crucial to continued improvement.

“It will also be critical to see how this approach affects outcomes in heart failure, reinfarction, mortality and left ventricular function.”

The study, appearing in Circulation: Journal of the American Heart Association, provides evidence the ACC’s leadership in the D2B Alliance for Quality is paying off in terms of quicker treatment for heart attacks. This results in lives saved, better quality of life after a heart attack, quicker recovery and reduced treatment costs, Holmes said.

“The goal of our D2B campaign is to improve the timeliness of lifesaving therapy for ST-elevation myocardial infarction (STEMI) patients at the nation’s hospitals that perform emergency angioplasty,” he said. “These remarkable results show that we are on the right track: in five short years we have achieved tremendous improvements in D2B times. This is a true testament to what we can accomplish with an evidence-based approach to quality improvement.”

ACC CEO Jack Lewin, M.D., said the D2B experience provides an example that should help shape health policy. It illustrates how evidence-based practice can reduce the cost of healthcare in the long term.

“This report illustrates how campaigns like the ACC’s D2B Alliance can reduce variation and improve patient outcomes and long-term health, with a documented 30 percent reduction in morbidity and mortality from cardiovascular disease over the past decade,” Lewin said.

“While doctors and hospitals are working together through the use of ACC data and the National Cardiovascular Data Registries to deliver quality care, we have received no incentives or rewards for this amazing progress,” he added. “Imagine if Medicare and private insurance companies would incentivize the diffusion of our registries and quality improvement tools and programs across the nation. Cardiovascular disease currently represents over 43 percent of Medicare costs, and we could save billions of dollars and millions of lives by applying the science and best practices we have already developed to the entire U.S. healthcare system.”

“The doctors and hospitals in the D2B Alliance receive no financial incentives, even though there are costs to participate. With new partnerships between the Centers for Medicare and Medicaid Services, employers and insurers, we could reduce cardiovascular morbidity and mortality by another 30 percent in the next ten years. Let’s do it.”

For more information:

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init